RT Journal Article
T1 Homocysteine pre-treatment increases redox capacity in both endothelial and tumor cells.
A1 Díaz-Santiago, Elena
A1 Rodríguez-Caso, Luis
A1 Cárdenas, Casimiro
A1 Serrano, José J
A1 Quesada, Ana R
A1 Medina, Miguel Ángel
K1 Bovine aortic endothelial cells
K1 Cysteine
K1 Homocysteine
K1 Homocysteine thiolactone
K1 MDA-MB231 breast cancer cell
K1 Redox
AB We studied the modulatory effects of homocysteine pre-treatment on the disulfide reduction capacity of tumor and endothelial cells. Human MDA-MB-231 breast carcinoma and bovine aorta endothelial cells were pre-treated for 1-24 hours with 0.5-5 mM homocysteine or homocysteine thiolactone. After washing to eliminate any rest of homocysteine or homocysteine thiolactone, cell redox capacity was determined by using a method for measuring disulfide reduction. Homocysteine pre-treatments for 1-4 hours at a concentration of 0.5-5 mM increase the disulfide reduction capacity of both tumor and endothelial cells. This effect cannot be fully mimicked by either cysteine or homocysteine thiolactone pre-treatments of tumor cells. Taken together, our data suggest that homocysteine can behave as an anti-oxidant agent by increasing the anti-oxidant capacity of tumor and endothelial cells.
YR 2016
FD 2016-05-19
LK http://hdl.handle.net/10668/10106
UL http://hdl.handle.net/10668/10106
LA en
DS RISalud
RD Jun 1, 2025